Protocol Ledger

NCT05797831 · Phase II/III · RECRUITING

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Interventional Phase II/III clinical trial protocol NCT05797831 sponsored by Kartos Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-17 Enrollment: 268 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05797831
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)268 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05797831
Protocol FieldVerified Registry Value
NCT IdentifierNCT05797831
Consolidated Lead SponsorKartos Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment268 participants (ESTIMATED)
Registered Start Date2023-07-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05797831
Hospital Research SiteLocationSite Profile
Northside HospitalAtlanta, GAOpen Hospital Dossier ->
Indiana UniversityIndianapolis, INOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI